rs3212986 A/C基因多态性与胃癌患者的化疗治疗结果无关：来自中国人群11篇出版物的证据。

rs3212986 A/C polymorphism is not associated with chemotherapy treatment outcomes in gastric cancer patients: evidence from 11 publications in Chinese populations.

作者信息

Tang Weiwei, Wang Hanjin, Wang Yuemei, Wang Xiaowei

机构信息

Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.

Department of Operation Anesthesiology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, People's Republic of China.

出版信息

Onco Targets Ther. 2017 Dec 20;11:1-8. doi: 10.2147/OTT.S148214. eCollection 2018.

DOI:10.2147/OTT.S148214

PMID:29302191

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5741989/

Abstract

BACKGROUND

A number of studies have investigated the roles of excision repair cross-complementation group 1 () gene rs3212986 polymorphisms as potential biomarkers in gastric cancer (GC). However, the results were inconsistent. Here, we performed a meta-analysis to explore rs3212986 polymorphisms in the chemotherapy response and clinical outcome of GC.

METHODS

PubMed, Embase, and Web of Science were searched up to July 28, 2017, for studies on the association between rs3212986 A/C polymorphisms and response to chemotherapy as well as overall survival time of GC. A fixed-effect or random-effect model was used to calculate the pooled odds ratios (ORs) based on the results from the heterogeneity tests.

RESULTS

The result revealed that there was no significant association between the rs3212986 A/C polymorphism and response to chemotherapy in GC under comparison models (AA + CA versus CC, OR 0.95, =0.80, AA versus CA, OR 0.85, =0.55, AA versus CC, OR 0.74, =0.47). Further identification suggested that rs3212986 A/C polymorphisms were not linked with the overall survival of GC (AA + CA versus CC, OR 1.09, =0.52, AA versus CA, OR 1.05, =0.85, AA versus CC, OR 1.43, =0.23).

CONCLUSION

Our meta-analysis indicated that the rs3212986 A/C polymorphism was not associated with response to chemotherapy or overall survival time in GC. Well-designed studies with larger sample sizes and more ethnic groups should be performed to further validate our results.

摘要

背景

多项研究探讨了切除修复交叉互补基因1（）rs3212986多态性作为胃癌（GC）潜在生物标志物的作用。然而，结果并不一致。在此，我们进行了一项荟萃分析，以探讨rs3212986多态性与GC化疗反应及临床结局之间的关系。

方法

检索截至2017年7月28日的PubMed、Embase和Web of Science数据库，查找关于rs3212986 A/C多态性与GC化疗反应及总生存时间相关性的研究。根据异质性检验结果，采用固定效应或随机效应模型计算合并比值比（OR）。

结果

结果显示，在比较模型下，rs3212986 A/C多态性与GC化疗反应之间无显著关联（AA + CA与CC相比，OR 0.95，=0.80；AA与CA相比，OR 0.85，=0.55；AA与CC相比，OR 0.74，=0.47）。进一步分析表明，rs3212986 A/C多态性与GC总生存无关（AA + CA与CC相比，OR 1.09，=0.52；AA与CA相比，OR 1.05，=0.85；AA与CC相比，OR 1.43，=0.23）。